Vancomycin or Linezolid Empiric MRSA Coverage with potential Ventilator Associated Pneumonia (pVAP) Has No Benefit or Effect on Outcomes: Antibiotic Stewardship Implications.

Related Articles

Vancomycin or Linezolid Empiric MRSA Coverage with potential Ventilator Associated Pneumonia (pVAP) Has No Benefit or Effect on Outcomes: Antibiotic Stewardship Implications.

Int J Antimicrob Agents. 2018 Jun 14;:

Authors: Cunha BA, Jaber N, Blum S

PMID: 29909171 [PubMed - as supplied by publisher]